FGF-2与肌肉减少症的研究进展
Research progress on FGF-2 and sarcopenia
  
DOI:10.3969/j.issn.1006-7108.2026.11.022
中文关键词:  FGF-2  肌少症  肌少-骨质疏松症
英文关键词:FGF-2  sarcopenia  osteosarcopenia
基金项目:山西省大健康产业高质量发展科研专项课题(DJKZXKT2023044)
作者单位
李锦江1 郝春艳2* 1.山西医科大学,山西 太原 030001 2.山西医科大学第一医院,山西 太原 030001 
摘要点击次数: 51
全文下载次数: 0
中文摘要:
      肌肉减少症(肌少症)是随年龄进展的骨骼肌退行性综合征。FGF-2作为关键肌因子,在肌少症中的作用极其复杂。一方面,FGF-2通过激活RAS/MAPK、PI3K/AKT、PLCγ等经典通路促进肌修复与再生;另一方面,FGF-2在衰老微环境中却可通过miR-29a/SPARC轴与CSPG4机制反常地促进肌内脂肪(IMAT)沉积。这种“双重作用”是目前FGF-2研究的核心矛盾。此外,FGF-2作为“肌-骨串扰”的信使,可通过抑制硬骨素(sclerostin)和肌生成抑制素(myostatin)发挥“肌-骨同治”的潜力,为“肌少-骨质疏松症”的干预提供了新思路。本文重点综述FGF-2在肌少症中的“双重作用”与“肌-骨串扰”机制,并探讨其作为生物标志物(如FGF2甲基化)和选择性调控靶点的临床转化挑战。
英文摘要:
      Sarcopenia is an age-progressive degenerative skeletal muscle syndrome. As a key myokine, the role of FGF-2 in sarcopenia is extremely complex. On one hand, FGF-2 promotes muscle repair and regeneration by activating classic pathways such as RAS/MAPK, PI3K/AKT, and PLCγ. On the other hand, in the aging microenvironment, FGF-2 can paradoxically promote intramuscular adipose tissue (IMAT) accumulation via the miR-29a/SPARC axis and CSPG4-dependent mechanisms. This "dual role" represents a core paradox in current FGF-2 research. Furthermore, as a messenger in "muscle-bone crosstalk," FGF-2 exhibits the potential for "dual muscle-bone therapy" by inhibiting sclerostin in bone and myostatin in muscle, offering new insights for osteosarcopenia interventions. This review focuses on the "dual role" and "muscle-bone crosstalk" mechanisms of FGF-2 in sarcopenia, and discusses the clinical translational challenges of using it as a biomarker (e.g., FGF2 methylation) and as a selective regulatory target.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=a189a74a38dc8eaad26eb38a231ce0f2d1865c0954d77b529a3f66d371678e37c846bd2bebd9b61e055351f0f6f3b21a&pcid=3b2e4763797f121df1e5c0ba55cffa7b&cid=b38b646414cdcf7db2ea2d31acb25be6&jid=eee368637b75dadee990b657cb57bb74&yid=a76b0c4434fafe5bbe1e66b98fe1e513&aid=&vid=&iid=3854e790332c10656a5748ff60214cbb&sid=742638178dfe1578391df3c253fae5aa&eid=7d4e89d473638abe00f72ffe590b5ecc&fileno=202611022&flag=1&is_more=0"> var my_pcid="3b2e4763797f121df1e5c0ba55cffa7b"; var my_cid="b38b646414cdcf7db2ea2d31acb25be6"; var my_jid="eee368637b75dadee990b657cb57bb74"; var my_yid="a76b0c4434fafe5bbe1e66b98fe1e513"; var my_aid="";